2022
No short-term mortality from benzodiazepine use post-acute ischemic stroke after accounting for bias
Moura L, Yan Z, Donahue M, Smith L, Schwamm L, Hsu J, Newhouse J, Haneuse S, Blacker D, Hernandez-Diaz S. No short-term mortality from benzodiazepine use post-acute ischemic stroke after accounting for bias. Journal Of Clinical Epidemiology 2022, 154: 136-145. PMID: 36572369, PMCID: PMC10033385, DOI: 10.1016/j.jclinepi.2022.12.013.Peer-Reviewed Original ResearchConceptsAcute ischemic strokeRisk differenceIschemic strokeBenzodiazepine useShort-term mortalityImmortal time biasElectronic health recordsAIS admissionsBenzodiazepine initiationStroke RegistryPoststroke mortalityTreatment initiationMortality riskPatientsFurther adjustmentMortalityBenzodiazepinesOlder adultsTime biasHealth recordsImmortal timeStrokeRiskDaysContraindications
2011
Are Quality Improvements in the Get With The Guidelines-Stroke Program Related to Better Care or Better Data Documentation?
Reeves M, Grau-Sepulveda M, Fonarow G, Olson D, Smith E, Schwamm L. Are Quality Improvements in the Get With The Guidelines-Stroke Program Related to Better Care or Better Data Documentation? Circulation Cardiovascular Quality And Outcomes 2011, 4: 503-511. PMID: 21828344, DOI: 10.1161/circoutcomes.111.961755.Peer-Reviewed Original ResearchConceptsGuidelines-Stroke programAtrial fibrillation/flutterIntravenous recombinant tissue plasminogen activator (rt-PA) therapyRecombinant tissue plasminogen activator therapyDeep vein thrombosis prophylaxisTissue plasminogen activator therapyBetter careTarget populationGWTG-Stroke hospitalsIschemic stroke admissionsPlasminogen activator therapyNumber of patientsProportion of subjectsData collection formDischarge antithromboticsEarly antithromboticsThrombosis prophylaxisTreatment contraindicationsEligible subjectsStroke admissionsActivator therapySmoking cessationLipid therapyMeasure complianceContraindications